touchCONGRESS

Advancing the treatment of MDS and AML: An update from ASH 2021

Access to this content is not permitted for healthcare professionals based in the US and UK.

Back to Education
Haematological Malignancies, Leukaemia Watch Time: 61 mins

touchCONGRESS Advancing the treatment of MDS and AML: An update from ASH 2021

Watch this two-part activity exploring recent data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML, filmed following the ASH 2021 Annual Meeting & Exposition.

Part 1: Watch leading haematology expert, Prof. Pierre Fenaux, review key data from ASH 2021 Watch Now
Part 2: Choose from three leading experts who discuss what these data may mean for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction and venetoclax
Sabatolimab, pevonedistat and triplet combinations
Targeting TP53, IDH and FLT3 mutations
CPX-351 and summary
Video Player Controls:
 
Leave Feedback
  • Part 2: Expert Interviews
Leave Feedback
Prof. Pierre Fenaux
Watch Time: 09:47 Hôpitaux de Paris Hospital Network, Paris, France

Prof. Pierre Fenaux considers the latest data on novel treatments for patients with higher-risk MDS and newly diagnosed AML from ASH 2021.
 
 
 
Leave Feedback
Dr Esther Oliva
Watch Time: 10:58 Grande Ospedale Metropolitano, Reggio Calabria, Italy

Dr Esther Oliva considers the latest data on novel treatments in higher-risk MDS and newly diagnosed AML from ASH 2021.
 
 
Leave Feedback
Prof. Andrew Wei
Watch Time: 10:47 Alfred Hospital, Melbourne, Australia

Prof. Andrew Wei considers the latest data on novel treatments in higher-risk MDS and newly diagnosed AML from ASH 2021.
 
Leave Feedback
Please Select A Video:
Prof. Pierre Fenaux
 Hôpitaux de Paris Hospital Network, Paris, France Watch Time: 09:47 Translations available:
Watch Video
Dr Esther Oliva
 Grande Ospedale Metropolitano, Reggio Calabria, Italy Watch Time: 10:58 Translations available:
Watch Video
Prof. Andrew Wei
 Alfred Hospital, Melbourne, Australia Watch Time: 10:47 Translations available:
Watch Video
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the latest data on novel treatments for higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia (AML) in this two-part activity. Filmed following ASH 2021.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the latest data for emerging therapeutic strategies for patients with HR-MDS
  • Summarize data for emerging treatments for patients with AML who are unfit for intensive chemotherapy
  • Discuss advances in treatment personalization and monitoring for patients with HR-MDS or AML
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from Novartis.
This activity is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals.

Launch date: 24 January 2022.

 

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72